BMJ Open  Cardiovascular and cerebrovascular health after pre-eclampsia: the Motherhealth prospective cohort study protocol

Eliza C Miller,1 Andrea Miltiades,2 Nicole Pimentel-Soler,3 Whitney A Booker,3 Ruth Landau-Cahana,2 Randolph S Marshall,1 Mary E D’Alton,3 Ronald Wapner,3 Kirsten Lawrence Cleary,3,4 Natalie Bello5

ABSTRACT

Introduction  Cardiovascular and cerebrovascular diseases (CCVDs) are the leading cause of maternal mortality in the first year after delivery. Women whose pregnancies were complicated by pre-eclampsia are at particularly high risk for adverse events. In addition, women with a history of pre-eclampsia have higher risk of CCVD later in life. The physiological mechanisms that contribute to increased CCVD risk in these women are not well understood, and the optimal clinical pathways for postpartum CCVD risk reduction are not yet defined.

Methods and analysis  The Motherhealth Study (MHS) is a prospective cohort study at Columbia University Irving Medical Center (CUIMC), a quaternary care academic medical centre serving a multiethnic population in New York City. MHS began recruitment on 28 September 2018 and will enrol 60 women diagnosed with pre-eclampsia with severe features in the antepartum or postpartum period, and 40 normotensive pregnant women as a comparison cohort. Clinical data, biospecimens and measures of vascular function will be collected from all participants at the time of enrolment. Women in the pre-eclampsia group will complete an additional three postpartum study visits over 12–24 months. Visits will include additional detailed cardiovascular and cerebrovascular phenotyping. As this is an exploratory, observational pilot study, only descriptive statistics are planned. Data will be used to inform power calculations for future planned interventional studies.

Ethics and dissemination  The CUIMC Institutional Review Board approved this study prior to initiation of recruitment. All participants signed informed consent prior to enrolment. Results will be disseminated to the clinical and research community, along with the public, on completion of analyses. Data will be shared on reasonable request.

INTRODUCTION

Cardiovascular and cerebrovascular diseases (CCVDs) are major causes of maternal mortality in the first year after delivery.1 Pre-eclampsia complicates 2%–8% of pregnancies,2 and these women are at particularly high risk of postpartum cardiovascular and cerebrovascular morbidity and mortality.3–8 In addition, mounting evidence shows that women with a history of pre-eclampsia have higher risk of CCVD later in life.9–11 The physiological mechanisms that contribute to increased CCVD risk in these women are incompletely understood,12–14 and optimum clinical pathways for postpartum CCVD risk reduction after pre-eclampsia are not clearly defined.15–17 Few prospective studies of women include detailed phenotypic information regarding pregnancy and its complications, and in the majority, the information has been collected retrospectively.18–20 An exception is the ongoing prospective Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-be (nuMoM2b) cohort study, which has already yielded important data regarding the effects of hypertensive pregnancy on future cardiovascular health.21 However, the women in this cohort had limited follow-up and cardiovascular physiological phenotyping in the first several...
years after delivery.\textsuperscript{22} Another cohort of high-risk women at a single centre demonstrated sustained hypertension and abnormal cardiovascular serum biomarkers in the year after delivery.\textsuperscript{23} These studies highlight the fact that significant gaps in knowledge remain regarding the effects of pre-eclampsia on maternal cardiovascular and cerebrovascular physiology in the first year postpartum. Furthermore, the American College of Obstetricians and Gynecologists and the American Heart Association have called for a collaborative approach to help reduce risk of CCVd in women after pregnancy complications.\textsuperscript{24}

To address these knowledge gaps, we are conducting the Motherhealth Study (MHS), an observational cohort study of women with and without pre-eclampsia with severe features in the first 12–24 months after delivery. This pilot feasibility study was conceived through ongoing, informal discussions in a multidisciplinary Pre-eclampsia Working Group at Columbia University Irving Medical Center (CUIMC). This academic forum includes clinicians and researchers of all levels (fellows, junior faculty and senior faculty) from the Departments of Obstetrics and Gynecology, Anesthesiology, Neurology and Medicine, with the explicit goals of presenting pilot data, brainstorming new hypothesis-driven research and resource sharing. The goal of the MHS is to demonstrate feasibility and collect pilot data to guide effect estimates for the planning of a future larger study involving multiple centres and longer-term follow-up. The study began recruitment on 28 September 2018 and is ongoing, with anticipated completion of recruitment by 31 December 2020 and completion of follow-up visits by 31 December 2022. Here, we describe the MHS methods and protocol.

**METHODS AND ANALYSIS**

MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research. MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research. MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research. MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research. MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research. MHS is a pilot prospective cohort study at CUIMC, an urban quaternary care academic medical centre serving a multiethnic population in New York City. Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research.

**Eligibility screening**

The screening process for both study groups takes place when a patient is admitted to an outpatient prenatal clinic, inpatient antepartum service, labour and delivery floor or postpartum inpatient unit. An eligibility checklist and screening log form is completed by study personnel at the time of the delivery hospitalisation for the normotensive comparison group. As the protocol differs slightly for the two groups, some study procedures are described separately by group.

| Table 1 | Eligibility criteria for Motherhealth Study |
|-----------------------------|----------------------------------|-----------------------------|
| **Cohort group** | **Inclusion criteria** | **Exclusion criteria** |
| Pregnant or postpartum women with PEC with severe features | &gt; Pregnant or postpartum women (within 12 weeks of delivery) | &gt; Contraindication to MRI |
|  | &gt; 18 years of age or older | &gt; Current substance abuse or addiction |
|  | &gt; PEC (including superimposed PEC) with severe features as defined by ISSHP 2018 Guidelines | &gt; Positive SARS-CoV-2 screening on hospital admission* |
| Normotensive pregnant women | &gt; Pregnant women | &gt; Current substance abuse or addiction |
|  | &gt; 18 years of age or older | &gt; History and/or current diagnosis of PEC |
|  | &gt; Normotensive | &gt; Hypertensive and/or any history of hypertensive disorder in current and/or previous pregnancy |
|  |  | &gt; History of stroke, epilepsy, traumatic brain injury, multiple sclerosis or other chronic brain or neurological disease EXCEPT migraine |

*Active SARS-CoV-2 infection was added as an exclusion criterion on 3 June 2020 after the COVID-19 pandemic began, due to safety concerns. BP, blood pressure; ISSHP, International Society for Study of Hypertension in Pregnancy; PEC, pre-eclampsia."
while screening the patient’s electronic medical record for verification of eligibility criteria. Each screened patient, regardless of cohort group, eligibility or enrolment status generates a study ID number, creating a study record. Eligibility status for consented participants is reviewed and certified by the principal investigator within 1 month of consent. Recruitment tools consisting of study brochures, study information cards and a contact referral form detailing participation procedures and study personnel’s contact information are available for both cohort groups.

**Patient and public involvement**

Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research.

**Overview of study protocol**

Study participation procedures and duration differ by cohort group. The pre-eclampsia group completes a series of up to four visits: a baseline ‘birth visit’ (V1) and up to three follow-up visits (V2, V3, V4). The normotensive comparison group completes one baseline visit at the time of the delivery hospitalisation (V1). V1 entails similar procedures for both groups, and all participants receive a US$50.00 compensation for the completion of V1. Each of the follow-up visits for the pre-eclampsia group addresses a particular aspect of the participant’s health (figure 1). The first follow-up visit for the pre-eclampsia cohort, V2, focuses on postpartum/obstetrical health, and may be merged or take place on the same day as the participant’s clinical postpartum visit. It takes place at 4–24 weeks postpartum. The estimated total duration of this follow-up visit is 1.5 hours and participants are compensated US$50.00 at the time of the visit. The next follow-up visit for the pre-eclampsia cohort, V3, focuses on cardiovascular health and takes place 6–12 months postpartum.

Note: A series of up to two consecutive study follow-ups for the pre-eclampsia cohort may be consolidated into a single visit under certain circumstances. This study element was instituted in the setting of the COVID-19 pandemic to limit exposure for study subjects. Elements that are completed at the merged visit and are not conditional on completion at a prior study visit will be completed only once during the merged visit (ie, if a study element is repeated at each of the standalone visits, it is not to be completed twice at the merged visit). Visit duration for merged follow-up visit(s) will depend on the types of visits merged and study visit procedures to be completed. However, it is estimated that no merged follow-up visit will take more than 2.5 hours. Compensation for merged visits will be commensurate with the compensation awarded for each of the standalone visits completed. Estimated duration of total study participation is 12–24 months for the pre-eclampsia group and 96 hours for the normotensive group.

**Visit 1 (birth visit) protocol**

The birth visit takes place during a consented participant’s hospital admission to the antepartum, labour or postpartum unit. Participants in the pre-eclampsia cohort may be consented any time after 20 weeks gestation and up to 12 weeks postpartum; for participants consented in the postpartum period, timelines are modified and not all birth visit procedures may be completed. Normotensive patients are consented only antepartum or intrapartum.

**Birth specimen collection**

Specimen collection for V1 consists of maternal blood, cerebrospinal fluid, placental samples and umbilical cord blood. Each specimen has a specific time frame for collection and processing (table 2). Study personnel will only collect specimens within the denominated time frame. All samples are labelled with study ID number, date and time.
Table 2 Time frame for specimen collection, birth visit

<table>
<thead>
<tr>
<th>Birth specimen type</th>
<th>Time frame for collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal blood</td>
<td>After consent/study enrolment and prior to discharge, preferably intrapartum</td>
</tr>
<tr>
<td>Placenta</td>
<td>At time of delivery, no later than 2 hours postpartum</td>
</tr>
<tr>
<td>Cord blood</td>
<td>At time of delivery, no later than 15 min after delivery</td>
</tr>
<tr>
<td>Cerebrospinal fluid</td>
<td>At time of neuraxial analgesia, if performed (either spinal or combined spinal-epidural)</td>
</tr>
</tbody>
</table>

of collection, date and time of processing and specimen type. Data regarding the collection and processing of each specimen are recorded in the study database. Should any sample be removed from the freezer for analysis and/or thawed for any reason, this is recorded in the study database. Specimen collection protocols are detailed in online supplemental appendix A. Planned analyses include angiogenic profiles, inflammatory and cytokine profiles and biomarkers of cardiovascular disease. In addition, samples will be banked for future use.

Dynamic cerebral autoregulation monitoring
A 10-minute dynamic cerebral autoregulation study using transcranial Doppler (TCD) and continuous non-invasive blood pressure monitoring using finger plethysmography is completed postpartum for all participants during V1, within 7 days after delivery or at the time of enrolment, if consented after 7 days postpartum. Details of this monitoring protocol have been previously published.26 27

Neurologic evaluation
A brief neurologic evaluation is completed during V1 for all participants, consisting of a focused neurological history, including history of migraines and presence or absence of aura; current neurological symptoms including headache, blurred vision or any other focal symptoms; a baseline modified Rankin scale (mRS)28 and a neurological exam, including a standard National Institutes of Health Stroke Scale (NIHSS).29 Examinations are completed by a board-certified or board-eligible neurologist certified in administration of the NIHSS and mRS.

Endothelial function assessment
A non-invasive endothelial function assessment using EndoPat (Itamar Medical) will be performed at the bedside on the postpartum floor 36–72 hours post delivery. Pneumatic probes are fitted on both index fingers. A 5-min brachial artery occlusion is performed with a sphygmomanometer to induce flow-mediated reactive hyperaemia; the ratio of the readings before and after occlusion are then used to calculate the score for endothelial function and reported as the reactive hyperaemia index. If a participant is consented during a postpartum admission, they will not complete the assessment. The participant must not be receiving any intravenous medication (eg, magnesium) at the time of the assessment and must fast for 4 hours prior to the assessment. For this reason, these assessments are scheduled early in the morning whenever possible. Additional details of the EndoPat assessment are included in online supplemental appendix B.

Self-reported measures
Prior to hospital discharge, all participants complete questionnaires pertaining to the birth visit (online supplemental appendix C). These include self-reported demographic data, medical history and pregnancy history.

Visit 2 protocol (pre-eclampsia group only)
Participants in the pre-eclampsia group complete V2 within 4–24 weeks after delivery. This broad time range was adopted to accommodate participants who are enrolled postpartum or who have difficulty with scheduling the visit due to medical issues or family circumstances. The visit includes a series of body measurements including weight, height, waist circumference, hip circumference and blood pressure, following standard procedures and using a validated blood pressure device (Omron). A survey addressing medication intake at the time of visit, breastfeeding status and healthcare utilisation up to time of visit is administered by study personnel and participant responses are recorded in the study database. Survey details are included in online supplemental appendix C. Maternal blood is collected, consisting of two 6 mL serum separator yellow top tubes. If maternal blood was not collected during V1, a ‘catchup collection’ consisting of one 6 mL EDTA purple top tube is collected at the time of this visit in addition to the routine V2. Processing for the 6 mL EDTA tube will follow steps outlined for the same specimen type in V1. A clean catch urine sample will also be completed at this visit. If endothelial function (EndoPat) testing was completed at V1, a repeat EndoPat test is also performed at V2 using the same protocol. Similarly, if TCD was performed at V1, a repeat TCD is included in V2 using the same protocol.

Visit 3 protocol (pre-eclampsia group only)
Participants in the pre-eclampsia group complete V3 within 6–12 months after delivery. The visit includes repeat body measurements including weight, height, waist circumference, hip circumference and blood pressure according to the same protocol as V2. If endothelial function (EndoPat) testing was completed at V1 and a repeat test was not completed at V2, a third EndoPat test is performed at V3 using the same protocol. A survey addressing medication intake at the time of visit, breastfeeding status, contraception and healthcare utilisation up to time of visit is administered by study personnel...
and participant responses are recorded in the study database. Survey details are included in online supplemental appendix C. A standard 12 lead ECG and echocardiogram without contrast are obtained according to the American Society of Echocardiography recommendations.

**Visit 4 protocol (pre-eclampsia group only)**

Participants in the pre-eclampsia group complete V4 within 12–24 months after delivery. The duration of the visit is expected to be 1.5–2 hours. The visit includes repeat body measurements including weight, height, waist circumference, hip circumference and blood pressure according to the same protocol as V2 and V3. ‘Catch-up’ procedures including repeat EndoPat testing and maternal blood collection are performed, if needed, according to previously described protocols. A survey addressing medication intake at the time of visit, breastfeeding status, contraception and healthcare utilisation up to time of visit is administered by study personnel and participant responses are recorded in the study database. Survey details are included in online supplemental appendix C. Cognitive testing is performed using the National Institutes of Health (NIH) Toolbox in either English or Spanish, depending on the participant’s preferred primary language. Tests are administered using a tablet, keyboard and laminated ‘home’ button sheet according to NIH Toolbox protocol. Cognitive testing includes the following tests from the NIH Toolbox, in the following order: List Sorting Working Memory Test Age 7+ v2.1; Pattern Comparison Processing Speech Age 7+ v2.1; Flanker Inhibitory Control and Attention Test Age 12+ v2.1 and Dimensional Change Card Sort Test Age 12+ v2.1. Following cognitive testing, MRI of the brain without contrast enhancement is performed on a 3 Tesla magnet, including the following sequences: diffusion-weighted imaging, T1, T2, fluid-attenuated inversion recovery, susceptibility-weighted imaging and magnetic resonance angiography.

**DATA ANALYSIS PLAN**

Descriptive statistics will be summarised using percentages for categorical variables and mean (SD) or median (IQR) for continuous variables depending on their distribution. For repeated measures, we will use generalised estimating equations and/or mixed methods to assess changes over time within individual participants. As normotensive women are currently planned to complete one study visit due to funding constraints, only outcome measures from the first study visit will be compared between cohorts. Continuous variables will be compared among women with and without pre-eclampsia using Student’s t-tests for normally distributed variables and Wilcoxon rank-sum or Kruskal-Wallis test for non-normally distributed variables. Categorical variables will be compared using χ² or non-parametric tests as appropriate. Further analysis will include stratification by onset (early onset before 34 weeks gestational age, late onset or postpartum).

**ETHICS, SAFETY PROTOCOLS AND DISSEMINATION OF RESULTS**

The Institutional Review Board (IRB) approved this study prior to initiation of recruitment. All participants sign informed consent prior to enrolment following all established IRB guidelines. Data are stored on a secure, encrypted online database (Research Electronic Data Capture (REDCap), a secure, web-based application designed to support data capture for research studies) and accessible only to study personnel in accordance with standard protocols. Biospecimens are stored per standard protocols as detailed in online supplemental appendix A and identified by each participant’s unique deidentified study ID. Standardised safety protocols have been established for adverse events including elevated blood pressures at follow-up visits, new symptoms reported by the participant and abnormal radiographic findings (online supplemental appendix D). Results will be disseminated to the clinical and research community via abstract presentation at professional meetings and manuscript publication, as soon as analyses are completed. All data, including biospecimens, will be shared on reasonable request from qualified investigators after approval from the study steering committee.

**STRENGTHS, LIMITATIONS AND FUTURE DIRECTIONS**

Strengths of the MHS include its multidisciplinary nature and the detailed physiological profiling offering robust pilot data for future studies. Limitations of this pilot study include its small sample size, limiting power to study between-group differences; its limitation to a single academic medical centre, limiting the generalisability of our results; its modest follow-up time of 24 months and its lack of follow-up visits for the control group. The results of this feasibility study will serve to demonstrate effect sizes and help to plan future larger and longer-term studies of the cardiovascular and cerebrovascular effects of pre-eclampsia.

**Author affiliations**

1Department of Neurology, Columbia University, New York, New York, USA
2Department of Anesthesiology, Columbia University, New York, New York, USA
3Department of Obstetrics and Gynecology, Columbia University, New York, New York, USA
4Department of Obstetrics and Gynecology, Yale University, New Haven, Connecticut, USA
5Department of Medicine, Cardiology Division, Columbia University, New York, New York, USA

**Twitter** Eliza C Miller @ElizaMillerMD

**Acknowledgements** The authors acknowledge Michelle DiVito, Caroline Torres and Casandra Almonte for their assistance in the implementation of the study protocol.

**Contributors** The authors confirm that they have met the following authorship criteria: Substantial contributions to the conception or design of the work (ECM, AM, RL-C, RSM, RW, MED, KLC, NB); or the acquisition, analysis or interpretation of data (ECM, AM, NP-S, WAB, RSM, NB); drafting the work or revising it critically for important intellectual content (ECM, AM, NP-S, WAB, RL-C, RSM, MED, RW, KLC, NB); gave final approval of the version published (ECM, AM, NP-S, WAB, RL-C, RSM, MED, RW, KLC, NB) and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work.
are appropriately investigated and resolved (ECM, AM, NP-S, WAB, RL-C, RSM, MED, RW, KLC, NB).

Funding This work is funded by grants from the National Institutes of Health, National Centre for Advancing Translational Sciences (ULTR001873), the National Institutes of Health, National Institute of Neurological Disorders and Stroke (K23NS107645), the Columbia University Irving Institute Clinical Trials Office, the Louis Katz Foundation (grant number not applicable), and the Louis V. Gerstner Jr Foundation (Gerstner Scholars Programme, grant number not applicable).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omission arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Eliza C Miller http://orcid.org/0000-0002-7108-8906

REFERENCES


